We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The efficacy of VESIcare LS for the treatment of neurogenic detrusor overactivity (NDO) was established in two clinical trials with a total of 95 pediatric NDO patients, ages two to 17 years old.